What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?

Expert Opin Drug Metab Toxicol. 2023 Jan-Jun;19(5):243-247. doi: 10.1080/17425255.2023.2223961. Epub 2023 Jun 13.

Authors

Sara Bettonte^{1

2}, Mattia Berton^{1

2}, Catia Marzolini^{1

2

3}

Affiliations

¹ Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital, Basel, Switzerland.
² Faculty of Medicine, University of Basel, Basel, Switzerland.
³ Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

PMID: 37293864
DOI: 10.1080/17425255.2023.2223961

No abstract available

Keywords: Long-acting; cabotegravir; drug-drug interactions; intramuscular; rilpivirine.

Publication types

Editorial

MeSH terms

Anti-HIV Agents* / pharmacology
Drug Interactions
HIV Infections* / drug therapy
Humans
Pyridones / pharmacokinetics
Rilpivirine / pharmacokinetics
Rilpivirine / therapeutic use

Substances

Rilpivirine
cabotegravir
Pyridones
Anti-HIV Agents